THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.

: 10/603,094

Applicant

: Don J. DIAMOND

Filed

: June 25, 2003

TC/A.U.

: 1645

Examiner

: To Be Assigned

Docket No.

: 1954-410

Customer No.

: 06449

Confirmation No.

: 7356

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Director of the United States Patent and Trademark Office P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant submits herewith copies of publications that the Office may wish to consider in examination of the subject application. The publications are listed on the attached form PTO-1449. Applicants do not admit that the cited references are prior art to the present application.

Respectfully submitted,

Martha Cassidy

Attorney for Applicants Registration No. 44,066

ROTHWELL, FIGG, ERNST & MANBECK, p.c.

Suite 800, 1425 K Street, N.W.

Washington, D.C. 20005 Telephone: (202)783-6040

MC: twg

Enclosure(s):

Form PTO-1449 (w/References)

1954-410.ids.wpd

INFORMATION DISPLOSURE				Complete if Known			
				Application Number 10/603,094		10/603,094	
				Filing Date		June 25, 2003	
STATEMENT BY APPLICANT			First Named Inventor		Don J. DIAMOND		
			Group Art Unit		1645		
			Examiner Name		To Be Assigned		
Sheet	1	of	3	Attorney	Docket Number	mber 1954-410	
				U.S. PATEN	NT DOCUMENTS		
		U.S. Pate	ent Docum	ent	Name of Pate	entee or Applicant	Date of Publication
Examiner Initials*	Cite No.1	Number		(ind Code ²	of Cited Document		of Cited Document MM-DD-YYYY
	1,	110 57	26 1 12		CET	TE et el	04/07/1008

		U.S. Patent Docume	nt	Name of Patentee or Applicant	Date of Publication
Examiner Initials*	Cite No. ¹	Number Kind Code (if known)		of Cited Document	of Cited Document MM-DD-YYYY
	1A	U.S. 5,736,142		SETTE et al.	04/07/1998
	1B	U.S. 6,472,375	B1	HOON et al.	10/29/2002
	1C	U.S. 6,514,948	B1	RAZ et al.	02/04/2003
	1D	U.S. 6,632,435	B1	DIAMOND	10/14/2003
		:			
				· 	
	<u> </u>				
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

		Complete if Known						
INFORMATION DISCLOSURE STATEMENT BY APPEICANT			Application Number 10/603,094					
			Filing Date	June 25, 2003				
			First Named Inventor	Don J. DIAMOND				
		Web 5 0 some co	Group Art Unit	1645				
			Examiner Name	To Be Assig	gned			
Sheet	2	TRADEMIN'S	Attorney Docket Number	1954-410				
			ATENT LITERATURE DOCU	MENTS				
Examiner Initials* Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published						T ²		
	1E		ity T Helper Epitope Induces Coction Against Viral Infection," J. C					
	1F	ALEXANDER et al., "A Decaepitope Polypeptide Primes for Multiple CD8+ INF-γ and Th Lymphocyte Responses: Evaluation of Multiepitope Polypeptides as a Mode for Vaccine Delivery," J. Immunol., 168:6189-6198, 2002.						
	1G	CAFARO et al., "Vaccination with DNA Containing tat Coding Sequences and Unmethylated CpG Motifs Protects Cynomolgus Monkeys Upon Infection with Simian/Human Immunodeficiency Virus (SHIV89.6P)," Vaccine, 19:2862-2877, 2001.						
	1H	CHEE et al., "Analysis of the Protein-Coding Content of the Sequence of Human cytomegalovirus Strain AD169," Curr. Topics Microbiol. Immunol., 154:126-169, 1990.						
	1I CHO et al., "Immunostimulatory DNA-based Vaccines Induce Cytotoxic Lymphocyte Activity T-Helper Cell-Independent Mechanism," Nat. Biotechnol., 18:509-514, 2000.							
	1J	CHO et al., "IFN-αβ Promo	et al., "IFN-αβ Promote Priming of Antigen-Specific CD8+ and CD4+ T Lymphocytes by unostimulatory DNA-Based Vaccines," J. Immunol., 168:4907-4913, 2002.					
1K ELIAS et al., "Strong Cytosine-Guanosine-Independent Immunostimulation in Humans a Primates by Synthetic Oligodeoxynucleotides with PyNTTTTGT Motifs," J. Immunol., 17: 2003.								
	1L	GÜRSEL et al., "Differential and Competitive Activation of Human Immune Cells by Distinct Classes of CpG Oligodeoxynucleotide," J. Leukocyte. Biol., 71:813-820, 2002.						
HO et al., "An Immunomodulatory GpG Oligonucleotide for the Treatment of Autoimmunity Innate and Adaptive Immune Systems," J. Immunol., 171:4920-4926, 2003. KHATTAB et al., "Three T-Cell Epitopes Within the C-Terminal 265 Amino Acids of the Mappe5 of Human Cytomegalovirus Recognized by Human Lymphocytes," J. Med. Virol., 52								
	1O KLINMAN et al., "CpG DNA: Recognition by and Activation of Monocytes," Microbes Infection 4:897-901, 2002.							
	1P	KRUG et al., "Identification of CpG Oligonucleotide Sequences with High Induction of IFN-α/β in Plasmacytoid Dendritic Cells," Eur. J. Immunol., 31:2154-2163, 2001.						
Examiner				Date				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered

Signature

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

			Complete if Known					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number 10/603,094					
			Filing Date	June 25, 2003 Don J. DIAMOND				
			First Named Inventor					
		50	Group Art Unit	1645				
	APR 2 0 2005 (3)		Examiner Name	To Be Assigned				
Sheet	3	of of	Attorney Docket Number	1954-410				
		NON P	ATENT LITERATURE DOCU	MENTS				
Examiner Initials*	$oldsymbol{1}$					T ²		
	1Q	MESEDA et al., "Prime-Boost Immunization with DNA and Modified Vaccinia Virus Ankara Vectors Expressing Herpes Simplex Virus-2 Glycoprotein D Elicits Greater Specific Antibody and Cytokine Responses than DNA Vaccine Alone," J. Infect. Dis., 186:1065-73, 2002.						
	1R	Cytotoxic T Lymphocytes," Eur. J. Immunol., 23:1215-1219, 1993. OSEROFF et al., "Pools of Lipidated HTL-CTL Constructs Prime For Multiple HBV and HCV CTL Epitope Responses," Vaccine, 16(8):823-833, 1998.						
	1S							
	1T							
	1U	SANO et al., "Oligodeoxynucleotides Without CpG Motifs Work as Adjuvant for the Induction of Th2 Differentiation in a Sequence-Independent Manner," J. Immunol., 170:2367-2373, 2003.						
	1V		Antigenic Epitopes Fused to Cationic Peptide Bound to Oligonucleotides eptor 9-Dependent, but CD4+ T Cell Help-Independent, Priming of CD8+71:5198-5207, 2003.					
	1W	SHIRAI et al., "Helper-Cytotoxic T Lymphocyte (CTL) Determinant Linkage Required for Priming of Anti-HIV CD8+ CTL in Vivo with Peptide Vaccine Constructs," J. Immunol., 152:549-556, 1994.						
1X SOLACHE et al., "Identification of Three HLA-A*0201-Restricted Cytotoxic T Cell Epito Cytomegalovirus Protein pp65 That Are Conserved Between Eight Strains of the Virus 163:5512-5518, 1999.								
	1Y	SPAETE et al., "Human Cytomegalovirus Strain Towne Glycoprotein B is Processed by Proteolytic Cleavage," Virology 167:207-225, 1988.						
1Z VERTHELYI et al., "Human Peripheral Blood Cells Differentially Recognize and Respond to Tw Distinct CpG Motifs," J. Immunol., 166:2372-2377, 2001.					e and Respond to Two			
· · · · · · · · · · · · · · · · · · ·						_		
Examiner	'	<u> </u>		Date				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered

Signature

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.